News & Analysis as of

Pharmaceutical Industry › Partnerships › Teva Pharmaceuticals

Goodwin

Teva and Fosun Partner to Develop a Novel Immunotherapy Targeting Melanoma and Other Cancers

Goodwin on

Teva Pharmaceutical Industries Ltd. (“Teva”) and Shanghai Fosun Pharmaceutical (Group) Co. (“Fosun Pharma”) recently announced a partnership to accelerate the development of Teva’s TEV-56278, a novel fusion protein that uses...more

Goodwin

Teva and Samsung Bioepis Announce U.S. Launch of EPYSQLI® (eculizumab-aagh), a SOLIRIS® Biosimilar

Goodwin on

On April 7, 2025, Teva Pharmaceuticals and Samsung Bioepis Co., Ltd. announced the U.S. launch of EPYSQLI® (eculizumab-aagh), a biosimilar referencing Alexion Pharmaceuticals’ SOLIRIS®....more

Goodwin

Alvotech and Teva Announce Acceptance of BLA for AVT05, a Golimumab Biosimilar

Goodwin on

​​​​​​​On January 27, 2025, Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar to SIMPONI and SIMPONI ARIA. This marks the first U.S. BLA acceptance for a...more

Goodwin

Teva and Alvotech Expand Strategic Biosimilars Partnership

Goodwin on

​​​​​​​Alvotech and Teva announced an expansion of their existing strategic partnership agreement relating to biosimilars products in the U.S.  According to the announcement, the existing agreement includes AVT02, an...more

Goodwin

Ranibizumab Biosimilar Program Updates

Goodwin on

This week, three development programs announced updates to their ranibizumab biosimilars. Ranibizumab is the active ingredient in Genentech’s LUCENTIS, which is indicated for retinal vascular disorders, including neovascular...more

Goodwin

Alvotech and Teva Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

Goodwin on

Today Alvotech and Teva announced that they have entered into an exclusive strategic partnership for the commercialization of five biosimilar candidates in the U.S. Under the partnership agreement, Alvotech will be...more

Goodwin

Celltrion/Teva and Amgen/Allergan Announce FDA Submissions for Proposed Biosimilars of Herceptin®

Goodwin on

Yesterday, two groups announced the submission of applications seeking FDA approval of biosimilars of Herceptin® (trastuzumab), which is indicated for the treatment of HER2-positive early breast cancer, adjuvant breast...more

Goodwin

FDA accepts Celltrion/Teva BLA for biosimilar of Rituxan®

Goodwin on

Celltrion and Teva announced today that the FDA has accepted for standard review their BLA for CT-P10 and that regulatory action is expected in the first quarter of 2018. CT-P10 is a proposed biosimilar to Rituxan®...more

Goodwin

Deal Watch: Teva and Celltrion Announce Biosimilar Commercial Partnership

Goodwin on

Teva Pharmaceutical Industries Ltd., Celltrion, Inc. and Celltrion Healthcare announced that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s biosimilar candidates: CT-P10, a...more

9 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide